Objective: To analyze the expression level and the correlation with clinical data of type X collagen α 1 chain (COL10A1) in the serum of breast cancer patients, so as to evaluate its predictive value for breast cancer risk. Methods: GEPIA database was used to analyze the expression of COL10A1 in breast cancer patients. The expression of COL10A1 in the serum of 30 breast cancer patients was detected by PCR, and its relationship with the clinical data of patients was analyzed. ROC curve was used to analyze the clinical diagnostic value of COL10A1 in breast cancer. The potential targets of COL10A1-mediated breast cancer were obtained through the Genecards database and OMIM database, and they were input into the STRING database to obtain the TSV file of the protein-protein interaction (PPI) network. GO enrichment analysis and KEGG enrichment analysis were used to explore different functional categories and related signal transduction pathways. Results: Bioinformatics analysis and PCR results showed that COL10A1 was highly expressed in breast cancer, which was closely related to histological grade, TNM stage, distant lymph node metastasis and Her2. ROC curve showed that the area under the curve of COL10A1 was 0.690 0 (95%CI: 0.5567-0.8233). When the optimal cut-off value was 1.1026, the sensitivity and specificity of COL10A1 in the diagnosis of breast cancer were 60.0% and 68.9%, respectively. A total of 14 potential targets of COL10A1-mediated breast cancer were obtained by combining the Genecards database with the OMIM database. A total of 241 GO terms were enriched by GO analysis, including 9 cellular components, 48 biological processes, and 12 molecular functions. KEGG enrichment analysis enriched a total of 12 signal transduction pathways. Conclusion: The high expression of serum COL10A1 in breast cancer patients is closely related to clinicopathological indicators, and has certain clinical value for breast cancer risk assessment.
GAO Liu
,
FAN Xinru
,
XIA Shicheng
,
YANG Jingrui
,
JIN Xin
,
YU Li
. Study on the value of serum COL10A1 detection for breast cancer risk prediction[J]. Journal of Baotou Medical College, 2025
, 41(6)
: 56
-63
.
DOI: 10.16833/j.cnki.jbmc.2025.06.011
[1] 厉雅婷, 房林. Teneurin跨膜蛋白1的生物信息学分析及其对乳腺癌MDA-MB-231细胞的增殖和迁移的影响[J]. 包头医学院学报, 2024, 40(7): 9-14.
[2] Benitez Fuentes JD, Morgan E, de Luna Aguilar A, et al. Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis[J]. JAMA Oncol, 2024, 10(1):71-78.
[3] Wu HX, Wang SP, Li GM, et al. Characterization of a novel COL10A1 variant associated with Schmid-type metaphyseal chondrodysplasia and a literature review[J]. Mol Genet Genomic Med, 2021, 9(5):e1668.
[4] Su H, Karin M. Multifaceted collagen-DDR1 signaling in cancer[J]. Trends Cell Biol, 2024, 34(5): 406-415.
[5] Ma B, Li FF, Ma BL. Down-regulation of COL1A1 inhibits tumor-associated fibroblast activation and mediates matrix remodeling in the tumor microenvironment of breast cancer[J]. Open Life Sci, 2023,18(1):20220776.
[6] Chen S, Wei Y, Liu HY, et al. Analysis of Collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics[J]. Bioengineered, 2021,12(1):127-137.
[7] Wang CY, Wang JR, Chen SY, et al. COL10A1 as a Prognostic Biomarker in Association with Immune Infiltration in Prostate Cancer[J]. Curr Cancer Drug Targets, 2024,24(3):340-353.
[8] Yi Q, Zhu GF, Zhu WJ, et al. Oncogenic mechanisms of COL10A1 in cancer and clinical challenges[J]. Oncol Rep, 2024,52(6):162.
[9] 杨靖瑞, 高榴, 许颖, 等. 长链非编码RNA NBR2在乳腺癌患者血清中的表达水平及临床意义[J]. 热带医学杂志, 2023, 23(7):890-894.
[10] 中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志, 2023, 33(12): 1092-1187.
[11] 张兆君, 孙杰克, 李健森, 等. 铜死亡相关基因LIPT1在乳腺癌中表达及免疫浸润预测[J]. 包头医学院学报, 2024, 40(8):1-6.
[12] Siadat SM, Ruberti JW. Mechanochemistry of collagen[J]. Acta Biomater, 2023,163:50-62.
[13] De Martino D, Bravo-Cordero JJ. Collagens in Cancer: Structural Regulators and Guardians of Cancer Progression[J]. Cancer Res, 2023,83(9):1386-1392.
[14] Ye YC, Li WH, Wang G, et al. Identification of a novel COL10A1:c.1952 G>T variant in a family with Schmid metaphyseal chondrodysplasia and development of a noninvasive prenatal testing method[J]. Mol Genet Genomic Med, 2021,9(10):e1758.
[15] Chen JN, Chen FZ, Wu X, et al. DLX5 promotes Col10a1 expression and chondrocyte hypertrophy and is involved in osteoarthritis progression[J]. Genes Dis, 2023,10(5):2097-2108.
[16] Xu QD, Zheng JT, Su ZG, et al. COL10A1 promotes tumorigenesis by modulating CD276 in pancreatic adenocarcinoma[J]. BMC Gastroenterol, 2023,23(1):397.
[17] He C, Liu WG, Xiong Y, et al. VSNL1 Promotes Cell Proliferation, Migration, and Invasion in Colorectal Cancer by Binding with COL10A1[J]. Ann Clin Lab Sci, 2022,52(1):60-72.
[18] Liang YK, Xia WJ, Zhang T, et al. Upregulated Collagen COL10A1 Remodels the Extracellular Matrix and Promotes Malignant Progression in Lung Adenocarcinoma[J]. Front Oncol, 2020,10:573534.
[19] Zhang MD, Chen HL, Wang ML, et al. Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer[J]. Biosci Rep, 2020,40(2):BSR20193286.
[20] Burston HE, Kent OA, Communal L, et al. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer[J]. J Clin Invest, 2021,131(7):e142677.
[21] He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy[J]. Signal Transduct Target Ther, 2021,6(1):425.
[22] Kwantwi LB. The dual and multifaceted role of relaxin-2 in cancer[J]. Clin Transl Oncol, 2023,25(10):2763-2771.
[23] Zhang HY, Chen LY, Zhao Y, et al. Relaxin-encapsulated polymeric metformin nanoparticles remodel tumor immune microenvironment by reducing CAFs for efficient triple-negative breast cancer immunotherapy[J]. Asian J Pharm Sci, 2023,18(2):100796.
[24] Siraj MA, Jacobs AT, Tan GT. Altersolanol B, a fungal tetrahydroanthraquinone, inhibits the proliferation of estrogen receptor-expressing (ER+) human breast adenocarcinoma by modulating PI3K/AKT, p38/ERK MAPK and associated signaling pathways[J]. Chem Biol Interact, 2022,359:109916.
[25] Bao C, Liu T, Qian LB, et al. Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway[J]. J Cancer, 2021,12(1):76-88.
